PALB2 and familial pancreatic carcinoma: A cohort of 29 advanced pancreatic cancer patients with deleterious germline mutations in BRCA1/BRCA2 or PALB2 had longer OS (median OS 21.8 months versus 8.1 months) than matched controls without mutations [50].